A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 650-656

  Dieras, V ^a   Chevallier, B ^b   Kerbrat, P ^c   Krakowski, I ^d   Roche, H ^e   Misset, J L ^f   Lentz, M A ^g   Azli, N ^h   Murawsky, M ^h   Riva, A ^h   Pouillart, P ^a   Fumoleau, P ^i,j  

^a INSTITUT CURIE   (France)

^b CRLCC Becquerel   (France)

^c CRLCC   (France)

^d CRLCC   (France)

^e CRLCC   (France)

^f HÔPITAL PAUL BROUSSE   (France)

^g Europ Organisation Res Treatm C   (Belgium)

^h SANOFI   (France)

ⁱ Service de Chirurgie Oncologique   (France)

^j Ctr Regionale Lutte Contre le C   (France)

more..

Author keywords

Antineoplastic agent; Breast neoplasm; Docetaxel

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; CORTICOSTEROID; DOCETAXEL; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; FEVER; FLUID RETENTION; HUMAN; HYPERSENSITIVITY REACTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LUNG METASTASIS; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PROGNOSIS; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; VISCERA; VOMITING; WEIGHT GAIN;

EID: 9444258045     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.416     Document Type: Article

References (35)

1. ANTMANN K AND SOUHAMI RL. (1993). High dose chemotherapy in solid tumors. Ann. Oncol., 4, S29-S44.
2. BISSERY MC, GUENARD D, GUERITTE VOEGELEIN F AND LAVELLE F. (1991). Experimental antitumour activity of Taxotere® (RP 56976, NSC 628503), a taxol analog. Cancer Res., 51, 4845-4852.
3. BISSETT D, SETANOIANS A, CASSIDY J, GRAHAM MA, CHADWICK GA, WILSON P, AUZANNET V, LE BAIL N, KAYE SB AND KERR DJ. (1993). Phase I and pharmacokinetic study of Taxotere® (docetaxel) (RP 56976) administered as a 24 hour infusion. Cancer Res., 53, 523-527.
4. BURRIS HA, IRVIN R, KUHN J, KALTER S, SMITH L, SHAFFER D, FIELDS S, WEISS G, ECKARDT J, RODRIGUEZ G, RINALDI D, WALL J, COOK G, SMITH S, VREELAND F, BAYSSAS M, LE BAIL N AND VON HOFF D. (1993). Phase I clinical trial of Taxotere® (docetaxel) given as either a 2-hour or 6-hour infusion. J. Clin. Oncol., 11, 950-958.
5. CHEVALLIER B, FUMOLEAU P, KERBRAT P, DIERAS V, ROCHE H, KRAKOWSKI I, AZLI N, BAYSSAS M, LENTZ MA AND VAN GLABBEKE M. (1995). Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol., 13, 214-222.
6. CHEBLOWSKI RT, SMALLEY RV, WEINER JM, IRWIN LE, BARTOLUCCI AA AND BATEMAN JR. (1989). Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long term survival. Br. J. Cancer, 59, 227-230.
7. CLARK GM, SLEDGE GW JR, OSBORNE CK AND MCGUIRE WL. (1987). Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J. Clin. Oncol., 5, 55-61.
8. Data on file [1], Rhône-Poulenc Rorer. Docetaxel. Investigators' Brochure, 30 November 1994.
9. Data on file [2], Rhône-Poulenc Rorer. Riva A. Metastatic breast cancer. Update of North American and European studies, October 1994 (updated Integrated Efficacy Analysis).
10. Data on file [3], Rhône-Poulenc Rorer. Final Medical Report, study TAX237.
11. Data on file [4], Rhône-Poulenc Rorer. Bizzari JP, Le Bail N. Integrated Safety Summary Updated Analysis, October 1994.
12. Data on file [5], Rhône-Poulenc Rorer. Final Medical Report, study TAX266.
13. Data on file [6], Rhône-Poulenc Rorer. Final Medical Report, study TAX228.
14. DE VALERIOLA D, BRASSINNE C, PICCART M, TOMIAK E, KERGER J, AWADA A, RAVOET C, LIPS S, AUZANNET V, LE BAIL N, BRUNO R AND KLASTERSKY J. (1992). Phase I pharmacokinetic study of Taxotere® (RP 56976, NSC 628503) administered as a weekly infusion (abstract). Proc. Am. Assoc. Cancer Res., 33, 1563.
15. EXTRA JM, ROUSSEAU F, BRUNO R, CLAVEL M, LE BAIL N AND MARTY M. (1993). Phase 1 and pharmacokinetic study of Taxotere® (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res., 53, 1037-1042.
16. FISHER B, SLACK N, KATRYCH D AND WOLMARK N. (1975). Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg. Gynecol. Obstet., 140, 528-534.
17. FLEMING T. (1982). One-sample multiple testing procedure for phase II clinical trials. Biometrics, 38, 143-151.
18. HANAUSKE AR, DEGEN D, HILSENBECK SG, BISSERY MC AND VON HOFF DD. (1992). Effects of Taxotere® and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs, 3, 121-124.
19. HARRIS JR, LIPPMAN ME, VERONESI U AND WILLETT W. (1992). Breast cancer (first of three parts). N. Engl. J. Med., 327, 319-328.
20. HARRIS JR, MORROW M AND BONADONNA G. (1993). Cancer of the breast. In Cancer: Principles and Practice of Oncology, 4th ed. De Vita T Jr, Hellman S, Rosenberg SA. (eds) pp. 1264-1332. JB Lippincott Co: Philadelphia.
21. HENDERSON IC. (1991). Chemotherapy for metastatic disease of breast cancer. In Breast Disease, 2nd ed. Harris J, Hellman S, Henderson IC, Kinne DW. (eds) pp. 604-665. JB Lippincott Company: Philadelphia.
22. HORTOBAGYI GN AND BUZDAR AU. (1993). Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs, 45 (suppl. 2), 10-19.
23. INOUE K, OGAWA H, HORIKOSHI N, AIBA K, MUKAIYAMA T, MIZUNUMA N, ITAMI S, HIRANO A, MATSUOKA A AND MATSUMURA T. (1991). Evaluation of prognostic factors for 233 patients with recurrent advanced breast cancer. Jpn. J. Clin. Oncol., 21, 334-339.
24. JENSEN OM, ESTEVE J, MOLLER H AND RENARD H. (1990). Cancer in the European Community and its member states. Eur. J. Cancer, 26, 1167-1256.
25. McPHERSON K, STEEL CM AND DIXON JM. (1994). Breast cancer epidemiology, risk factors, and genetics, Br. Med. J., 309, 1003-1006.
26. PAZDUR R, NEWMAN RA, NEWMAN BM, FUENTES A, BENVENUTO J, BREADY B, MOORE D, JAIYESIMI I, VREELAND F, BAYSSAS M AND RABER MN. (1992). Phase I trial of Taxotere®: five-day schedule. J. Natl Canter Inst., 84, 1781-1788.
27. RINGEL I AND HORWITZ SB. (1991). Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J. Natl Cancer Inst., 83, 288-291.
28. ROSS MB, BUZDAR AU, SMITH TL, ECKLES N, HORTOBAGYI GN, BLUMENSCHEIN GR, FREIREICH EJ AND GEHAN EA. (1985). Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer, 55, 341-346.
29. SCHRIJVERS D, WANDERS J, DIRIX L, PROVE A, VONCK I, VAN OOSTEROM A AND KAYE S. (1993). Coping with toxicities of docetaxel (Taxotere™). Ann. Oncol., 4, 610-611.
30. SEIDMAN AD, HUDIS C, CROWN JPA, BALMACEDA C, LEBWOHL D, CURRIE V, GILEWSKI T, HAKES T, ROBLES M, KLEM K, LEPORE J AND NORTON L. (1993). Phase II evaluation of Taxotere® (RP 56976; NSC 628503) as initial chemotherapy for metastatic breast cancer (abstract). Proc. Am. Soc. Clin. Oncol., 12, 52.
31. SIMON R. (1986). Confidence intervals for reporting results of clinical trials. Ann. Intern. Med., 105, 429-435.
32. SIMON R. (1989). Optimal two-stage design for phase II clinical trials. Controlled Clinical Trials, 10, 1-10.
33. TRUDEAU ME, EISENHAUER E, LOFTERS W, NORRIS B, MULDAL A, LETENDRE F, VANDENGURG T AND VERMA S. (1993). Phase II study of Taxotere® as first line chemotherapy for metastatic breast cancer (MBC). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study (abstract). Proc. Am. Soc. Clin. Oncol., 12, 59.
34. VALERO V, WALTERS R, THERIAULT R, ESPARZA L, HOLMES F, FRASCHINI G, PLASSE T, BELLET R, RABER M, BUZDAR A AND HORTOBAGYI G. (1994). Phase II study of docetaxel (Taxotere®) in anthracycline-refractory metastatic breast cancer (abstract). Proc. Am. Soc. Clin. Oncol., 13, 470.
35. WILLIAMS SF, MICH R, DESSER R, GOLICK J, BESCHORNER J AND BBITRAN JD. (1989). High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J. Clin. Oncol., 7, 1824-1830.